Wolverine Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $13.1M | Buy |
29,300
+13,300
| +83% | +$5.42M | 0.01% | 790 |
|
|
2025
Q2 | $5.17M | Sell |
16,000
-4,200
| -21% | -$1.16M | 0.01% | 1037 |
|
|
2025
Q1 | $5.42M | Buy |
20,200
+9,200
| +84% | +$2.36M | 0.01% | 949 |
|
|
2024
Q4 | $2.6M | Sell |
11,000
-5,700
| -34% | -$1.5M | ﹤0.01% | 1748 |
|
|
2024
Q3 | $4.59M | Sell |
16,700
-28,300
| -63% | -$7.37M | ﹤0.01% | 1102 |
|
|
2024
Q2 | $10.9M | Buy |
45,000
+22,900
| +104% | +$3.62M | 0.01% | 609 |
|
|
2024
Q1 | $3.3M | Buy |
22,100
+10,500
| +91% | +$1.75M | ﹤0.01% | 1264 |
|
|
2023
Q4 | $2.22M | Buy |
11,600
+3,700
| +47% | +$630K | ﹤0.01% | 1636 |
|
|
2023
Q3 | $1.4M | Buy |
7,900
+500
| +7% | +$95.4K | ﹤0.01% | 1850 |
|
|
2023
Q2 | $1.41M | Sell |
7,400
-900
| -11% | -$178K | ﹤0.01% | 1741 |
|
|
2023
Q1 | $1.62M | Sell |
8,300
-3,500
| -30% | -$736K | ﹤0.01% | 1515 |
|
|
2022
Q4 | $2.8M | Buy |
11,800
+2,000
| +20% | +$427K | ﹤0.01% | 1198 |
|
|
2022
Q3 | $2.05M | Buy |
9,800
+1,600
| +20% | +$305K | ﹤0.01% | 1395 |
|
|
2022
Q2 | $1.19M | Sell |
8,200
-800
| -9% | -$113K | ﹤0.01% | 1775 |
|
|
2022
Q1 | $1.49M | Buy |
9,000
+1,600
| +22% | +$244K | ﹤0.01% | 2038 |
|
|
2021
Q4 | $1.27M | Buy |
7,400
+2,800
| +61% | +$520K | ﹤0.01% | 2349 |
|
|
2021
Q3 | $816K | Sell |
4,600
-10,400
| -69% | -$1.95M | ﹤0.01% | 3272 |
|
|
2021
Q2 | $2.49M | Buy |
15,000
+12,800
| +582% | +$1.87M | ﹤0.01% | 1762 |
|
|
2021
Q1 | $297K | Sell |
2,200
-15,700
| -88% | -$2.36M | ﹤0.01% | 4484 |
|
|
2020
Q4 | $2.35M | Sell |
17,900
-6,100
| -25% | -$815K | ﹤0.01% | 1564 |
|
|
2020
Q3 | $3.48M | Sell |
24,000
-1,900
| -7% | -$270K | 0.01% | 1081 |
|
|
2020
Q2 | $3.83M | Sell |
25,900
-1,300
| -5% | -$175K | 0.01% | 971 |
|
|
2020
Q1 | $2.96M | Sell |
27,200
-27,000
| -50% | -$3.12M | 0.01% | 1059 |
|
|
2019
Q4 | $6.22M | Buy |
54,200
+9,900
| +22% | +$987K | 0.02% | 946 |
|
|
2019
Q3 | $3.59M | Buy |
44,300
+9,800
| +28% | +$775K | 0.01% | 1055 |
|
|
2019
Q2 | $2.5M | Sell |
34,500
-4,700
| -12% | -$361K | 0.01% | 1349 |
|
|
2019
Q1 | $3.66M | Sell |
39,200
-6,000
| -13% | -$502K | 0.01% | 1075 |
|
|
2018
Q4 | $3.18M | Sell |
45,200
-9,600
| -18% | -$738K | 0.01% | 1090 |
|
|
2018
Q3 | $4.8M | Sell |
54,800
-19,000
| -26% | -$1.91M | 0.01% | 1002 |
|
|
2018
Q2 | $8.79M | Hold |
73,800
| – | – | 0.02% | 566 |
|
|
2018
Q1 | $8.79M | Buy |
73,800
+18,700
| +34% | +$2.41M | 0.02% | 566 |
|
|
2017
Q4 | $7M | Buy |
+55,100
| New | +$6.92M | 0.03% | 669 |
|
|
2017
Q1 | – | Sell |
-41,700
| Closed | -$1.56M | – | 4166 |
|
|
2016
Q4 | $1.56M | Buy |
+41,700
| New | +$1.75M | 0.01% | 1532 |
|
Other funds holding ALNY
Wolverine Trading's ALNY Position: Q3 2025 in Review
Wolverine Trading increased its Alnylam Pharmaceuticals (ALNY) stake by 458% in Q3 2025, buying an estimated $2.09M and bringing the position to 6,262 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.
Wolverine Trading first reported a position in ALNY in Q4 2016 and has held it in 19 quarters since. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.
- Wolverine Trading held 6,262 shares of Alnylam Pharmaceuticals worth $2.8M as of Q3 2025.
- Wolverine Trading bought 5,140 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.09M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1879 holding.
- Wolverine Trading first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
- 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.